# OnCo record car-t-referral-and-eligibility (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/car-t-referral-and-eligibility/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "car-t-referral-and-eligibility" ;
  schema:name "Referral and eligibility assessment for CAR T-cell therapy"@en ;
  schema:alternateName "CAR-T referral"@en, "CAR T eligibility"@en, "CAR-T candidacy"@en, "who can have CAR T"@en, "CAR-T indications"@en ;
  schema:description "CAR T-cell therapy is given at specialist centres, and a team there decides. For large B-cell lymphoma that does not respond to first treatment or returns within a year, CAR T cells are now the standard next step, so early referral matters. The centre checks your fitness, heart, brain and blood, and you will need to stay near the hospital, with someone to help, for at least two weeks after."@en ;
  schema:url <https://onco.cc/protocols/car-t-referral-and-eligibility/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "cell-therapy", "car-t" ;
  onco:related <https://onco.cc/protocols/car-t-apheresis/>, <https://onco.cc/protocols/car-t-bridging/>, <https://onco.cc/protocols/car-t-lymphodepletion/>, <https://onco.cc/protocols/car-t-infection-prevention/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:drugs <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/idecabtagene-vicleucel/>, <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/drugs/obecabtagene-autoleucel/> ;
  onco:terms <https://onco.cc/terms/lymphoma-tx-car-t-pathway/> .